Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Selecting high priority quality measures for breast cancer quality improvement.

Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC.

Med Care. 2008 Aug;46(8):762-70. doi: 10.1097/MLR.0b013e318178ead3.

2.

Clinical application of the 70-gene profile: the MINDACT trial.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.

J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

PMID:
18258980
3.

Cancer statistics, 2007.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.

CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.

PMID:
17237035
4.

TAILORx: trial assigning individualized options for treatment (Rx).

Sparano JA.

Clin Breast Cancer. 2006 Oct;7(4):347-50. No abstract available.

PMID:
17092406
5.

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium..

J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92.

PMID:
16954471
6.

Concordance among gene-expression-based predictors for breast cancer.

Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM.

N Engl J Med. 2006 Aug 10;355(6):560-9.

7.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N.

J Clin Oncol. 2006 Aug 10;24(23):3726-34. Epub 2006 May 23.

PMID:
16720680
8.

Cancer statistics, 2006.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ.

CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30.

9.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. Review.

PMID:
16507275
10.

Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.

Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R.

J Clin Oncol. 2006 Feb 20;24(6):872-7.

PMID:
16484696
11.

A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network.

Christian CK, Niland J, Edge SB, Ottesen RA, Hughes ME, Theriault R, Wilson J, Hergrueter CA, Weeks JC.

Ann Surg. 2006 Feb;243(2):241-9.

12.

Update: NCCN breast cancer Clinical Practice Guidelines.

Carlson RW, McCormick B.

J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S7-11. No abstract available.

PMID:
16280118
13.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members..

Ann Oncol. 2005 Oct;16(10):1569-83. Epub 2005 Sep 7.

PMID:
16148022
14.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
15.

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L; Cancer and Leukemia Group B..

JAMA. 2005 Mar 2;293(9):1073-81.

PMID:
15741529
16.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N.

N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10.

17.

Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers.

Edge SB, Niland JC, Bookman MA, Theriault RL, Ottesen R, Lepisto E, Weeks JC.

J Natl Cancer Inst. 2003 Oct 15;95(20):1514-21.

PMID:
14559873
18.

Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients.

Palazzi M, De Tomasi D, D'Affronto C, Richetti A, Valli MC, Meregalli S, Asnaghi D, Arienti V, Cavallini D, Pradella R, Cafaro I, Baroncelli G, Di Lorenzo I, De Agostini A, Parrinello G, Bertoni F.

Tumori. 2002 Nov-Dec;88(6):503-6.

PMID:
12597147
19.

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.

Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS.

Ann Intern Med. 2003 Jan 21;138(2):90-7. Erratum in: Ann Intern Med. 2003 Nov 18;139(10):873.

20.

Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J.

J Natl Cancer Inst. 2002 Nov 6;94(21):1626-34.

PMID:
12419789

Supplemental Content

Support Center